PodParley PodParley
PodParley
MPR Weekly Dose 135 — Makena Panel Vote; Apixaban vs Rivaroxaban; Monkeypox Ocular Complications; Novavax COVID-19 Booster; Sparsentan, Tofersen Reviews Extended episode artwork

EPISODE · Oct 21, 2022 · 16 MIN

MPR Weekly Dose 135 — Makena Panel Vote; Apixaban vs Rivaroxaban; Monkeypox Ocular Complications; Novavax COVID-19 Booster; Sparsentan, Tofersen Reviews Extended

from MPR Weekly Dose

FDA Panel votes on the potential removal from the market of Makena; results from an apixaban trial of patients with atrial fibrillation and valvular heart disease; reports of serious ocular complications with monkeypox infection; the novavax vaccine becomes the latest authorized COVID-19 booster; and treatments for nephropathy and ALS have their review period extended.

Episode metadata supplied by the publisher feed · Published Oct 21, 2022

Embed this episode

Ready to play

MPR Weekly Dose 135 — Makena Panel Vote; Apixaban vs Rivaroxaban; Monkeypox Ocular Complications; Novavax COVID-19 Booster; Sparsentan, Tofersen Reviews Extended

0:00 16:29

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of MPR Weekly Dose?

This episode is 16 minutes long.

When was this MPR Weekly Dose episode published?

This episode was published on October 21, 2022.

Can I download this MPR Weekly Dose episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!